Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-651-8851
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees62
Next Earnings Date11/25/2019 (Estimated)
OptionableNot Optionable
Fulcrum Therapeutics (NASDAQ:FULC) Frequently Asked Questions
What is Fulcrum Therapeutics' stock symbol?
Fulcrum Therapeutics trades on the NASDAQ under the ticker symbol "FULC."
How were Fulcrum Therapeutics' earnings last quarter?
Fulcrum Therapeutics (NASDAQ:FULC) announced its quarterly earnings data on Monday, August, 26th. The company reported ($9.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($3.10) by $6.11. View Fulcrum Therapeutics' Earnings History.
When is Fulcrum Therapeutics' next earnings date?
What price target have analysts set for FULC?
3 Wall Street analysts have issued 12 month target prices for Fulcrum Therapeutics' stock. Their forecasts range from $19.00 to $29.00. On average, they anticipate Fulcrum Therapeutics' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 176.5% from the stock's current price. View Analyst Price Targets for Fulcrum Therapeutics.
What is the consensus analysts' recommendation for Fulcrum Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fulcrum Therapeutics.
Has Fulcrum Therapeutics been receiving favorable news coverage?
Press coverage about FULC stock has trended somewhat negative recently, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Fulcrum Therapeutics earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Fulcrum Therapeutics.
Who are some of Fulcrum Therapeutics' key competitors?
Some companies that are related to Fulcrum Therapeutics include ZEALAND PHARMA/S (ZEAL), Eagle Pharmaceuticals (EGRX), CannTrust (CNTTF), Endo International (ENDP), Kura Oncology (KURA), Cytokinetics (CYTK), Urogen Pharma (URGN), Vanda Pharmaceuticals (VNDA), Stoke Therapeutics (STOK), Rocket Pharmaceuticals (RCKT), Capstone Therapeutics (CAPS), ZIOPHARM Oncology (ZIOP), Catalyst Pharmaceuticals (CPRX), Advanz Pharma (CXRXF) and Vectura Group (VEGPF).
What other stocks do shareholders of Fulcrum Therapeutics own?
Who are Fulcrum Therapeutics' key executives?
Fulcrum Therapeutics' management team includes the folowing people:
- Dr. Robert J. Gould, CEO, Pres & Director (Age 64)
- Peter G. Thomson, VP of Fin. & Accounting
- Mr. Bryan E. Stuart, Chief Operating Officer (Age 43)
- Dr. Owen B. Wallace, Chief Scientific Officer (Age 50)
- Dr. Diego Cadavid, Sr. VP of Clinical Devel. (Age 53)
When did Fulcrum Therapeutics IPO?
(FULC) raised $76 million in an initial public offering on Thursday, July 18th 2019. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink served as the underwriters for the IPO.
When did Fulcrum Therapeutics' quiet period expire?
Fulcrum Therapeutics' quiet period expired on Tuesday, August 27th. Fulcrum Therapeutics had issued 4,500,000 shares in its public offering on July 18th. The total size of the offering was $72,000,000 based on an initial share price of $16.00. During Fulcrum Therapeutics' quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
How do I buy shares of Fulcrum Therapeutics?
Shares of FULC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Fulcrum Therapeutics' stock price today?
One share of FULC stock can currently be purchased for approximately $8.68.
How big of a company is Fulcrum Therapeutics?
What is Fulcrum Therapeutics' official website?
How can I contact Fulcrum Therapeutics?
Fulcrum Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-651-8851 or via email at [email protected]
MarketBeat Community Rating for Fulcrum Therapeutics (NASDAQ FULC)
| Community Ranking: | | 2.4 out of 5 ( ) |
| Outperform Votes: | | 9 (Thanks for Voting!) |
| Underperform Votes: | | 10 (Thanks for Voting!) |
| Total Votes: | | 19 |
